A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis

Archives of Neurology

Volumn 65, Issue 10, 2008, Pages 1358-1362

  Ragheb, Samia ^a,b   Lisak, Robert ^a   Lewis, Richard ^a   Van Stavern, Gregory ^a   Gonzales, Felicitas ^a   Simon, Kirk ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROLOGY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY FORMATION; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDICTIVE VALUE OF TESTS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SEX FACTORS; UP-REGULATION;

EID: 54049132513     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.10.1358     Document Type: Article

References (32)

1. Ragheb S, Lisak RP. The immunopathogenesis of acquired (autoimmune) myasthenia gravis. In: Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York, NY: Dekker; 1994:239-276.
2. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(pt 10):2304-2311.
3. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978-1980.
4. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A. 1980;77(2):755-759.
5. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane D. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology. 1976;26(11):1054-1059.
6. Ragheb S, Bealmear B, Lisak R. Cell-surface expression of lymphocyte activation markers in myasthenia gravis. Autoimmunity. 1999;31(1):55-66.
7. Wekerle H, Ketelsen UP, Zurn AP, Fulpius BW. Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived muscle cells. Eur J Immunol. 1978;8(8):579-583.
8. Ragheb S, Lisak RP. The thymus and myasthenia gravis. In: Kirschner PA, ed. Chest Surgery Clinics of North America: The Thymus. Philadelphia, PA: Saunders; 2001:311-327.
9. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol. 2001;167(4):1935-1944.
10. Murai H, Hara H, Hatae T, Kobayashi T, Watanabe T. Expression of CD23 in the germinal center of thymus from myasthenia gravis patients. J Neuroimmunol. 1997;76(1-2):61-69.
11. Liu Y-J, Mason DY, Johnson GD, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol. 1991;21(8):1905-1910.
12. Onodera J, Nakamura S, Nagano I, et al. Upregulation of bcl-2 in the myasthenic thymus. Ann Neurol. 1996;39(4):521-528.
13. Shiono H, Fujii Y, Okumura M, Takeuchi Y, Inoue M, Matsuda H. Failure to downregulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol. 1997;27(4):805-809.
14. Moore PA, Belvedere O, Orr A, et al. Blys: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260- 263.
15. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747-1756.
16. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97(1):198-204.
17. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-264.
18. Do RKG, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953-964.
19. Craxton A, Draves KE, Gruppi A, Clark EA. Baff regulates B cell survival by down-regulating the BH3-only family member Bim via the ERK pathway. J Exp Med. 2005;202(10):1363-1374.
20. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16-23.
21. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747.
22. Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem. 2007;101(5):1153-1160.
23. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313-1319.
24. Zhang J, Roschke V, Baker KP, et al. A role of B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6-10.
25. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/Blys overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest. 2002;109(1):59-68.
26. Fabris M, Visentini D, De Re V, et al. Elevated B cell-activating factor of the tumor necrosis factor family in coeliac disease. Scand J Gastroenterol. 2007;42(12):1434-1439.
27. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology. 1981;31(8):935-943.
28. Levinson AI, Zweiman B, Lisak RP, Dziarski A, Moskovitz AR. Thymic B-cell activation in myasthenia gravis. Neurology. 1984;34(4):462-468.
29. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature. 1994;371(6496):389-395.
30. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785-798.
31. Thangarajh M, Masterman T, Helgeland L, et al. The thymus is a source of B-cell-survival factors - APRIL and Baff - in myasthenia gravis. J Neuroimmunol. 2006;178(1-2):161-166.
32. + B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol. 2008;126(2):180-188.